CDK4/6 inhibitors

Ribociclib Plus Letrozole Shows Potent Activity in Recurrent Low-Grade Serous Ovarian Carcinoma: Results from GOG 3026

By MedXY 01/19/2026

The GOG 3026 phase II trial demonstrates that the combination of ribociclib and letrozole provides significant clinical benefit and durable responses in patients with recurrent low-grade serous carcinoma, representing a major step forward for this chemoresistant malignancy.

news Oncology

Neoadjuvant Abemaciclib plus Letrozole: A Potential Chemotherapy-Sparing Strategy in Select HR+/HER2- Breast Cancers?

By MedXY 01/11/2026

The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower genomic risk or moderate proliferation indices.

news Oncology Pathology & Lab Medicine

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

By MedXY 01/09/2026

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression, identifying superior combination regimens for specific genomic subgroups.

OB/GYN & Women's Health Oncology Specialties

Assessing the Nationwide Prevalence and Outcomes of Breast Cancer Patients Eligible for Adjuvant CDK4/6 Inhibitors

By MedXY 10/18/2025

This study offers insights into the prevalence, characteristics, and long-term survival of breast cancer patients eligible for adjuvant CDK4/6 inhibitors, highlighting real-world outcomes compared to clinical trial populations.

news Oncology Pathology & Lab Medicine Specialties

Circulating Tumor DNA as a Biomarker to Guide Timing of CDK4/6 Inhibitor Therapy in Advanced ER+ HER2− Breast Cancer

By MedXY 09/04/2025

Pretreatment circulating tumor DNA levels can predict which patients with advanced ER-positive, HER2-negative breast cancer benefit more from first-line CDK4/6 inhibitor therapy, supporting personalized treatment strategies.